Clinical Trial

The Effect of CB-Exo-A600 in Mild to Moderate Alzheimer's Disease

Study acronym: CB-EXOAD
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is divided into two phases: a dose-escalation phase and an expansion cohort phase. The dose-escalation phase is a single-center study, while the expansion cohort phase is a multicenter, prospective, randomized, double-blind, placebo-controlled study.
Protocol Amendment History 1 change
critical Recruitment opened 2026-05-23
Trial Details
NCT Number NCT07457125
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Carrier Biomed (Suzhou) Co., Ltd, Chinese Academy of Sciences
Conditions Mild to Moderate Alzheimer's Disease
Enrollment 33 participants
Start Date 2026-05-30
Primary Completion 2028-12-30 (estimated)
Study Completion 2028-12-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-22